Mitomycin-C induced hemolytic uremic syndrome: a case report.

Abstract

Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome. We report a patient with a colonic adenocarcinoma who developed hemolytic uremic syndrome after receiving 85 mg/m2 of the drug. The patient was left untreated and died 5 months after this diagnosis was made, of a second malignancy. Differential diagnosis and treatment of this condition are discussed.

• Authors: Rajaram K Gundappa, Kamal Sud, Harbir S Kohli, Krishan L Gupta, Kusum Joshi, Vinay Sakhuja
• Journal: Renal failure (Ren Fail) Vol. 24 Issue 3 Pg. 373-7 (May 2002) ISSN: 0886-022X [Print] England
• PMID: 12166705 (Publication Type: Case Reports, Journal Article)

Chemical References

• Alkylating Agents
• Antibiotics, Antineoplastic
• Mitomycin

Topics

• Adenocarcinoma (diagnosis, drug therapy)
• Alkylating Agents (adverse effects)
• Antibiotics, Antineoplastic (adverse effects)
• Colonic Neoplasms (diagnosis, drug therapy)
• Diagnosis, Differential
• Female
• Hemolytic-Uremic Syndrome (chemically induced, diagnosis)
• Humans
• Middle Aged
• Mitomycin (adverse effects)
• Renal Insufficiency (chemically induced, diagnosis)